comparemela.com

Latest Breaking News On - Won seog kim - Page 1 : comparemela.com

Anbalcabtagene Autoleucel Generates Responses in Relapsed/Refractory LBCL

The novel, autologous, anti-CD19 CAR T-cell therapy anbalcabtagene autoleucel produced durable responses and was well tolerated in patients with relapsed/refractory large B-cell lymphoma.

Soult ukpyolsiSouth koreaSeog kimDivision of hematologyOncology at samsun medical centerInternational conference on malignant lymphomaAnnualinternational conferenceWon seog kimSamsun medical centerInternational conferenceMalignant lymphomaCart cell therapy

Affimed Announces Acceptance of Abstracts at the 17th

A pre-clinical data set of AFM13 in combination with Artiva Biotherapeutics Inc.’s allogeneic NK cell AB-101 shows that AFM13 enhances the cytotoxic.

United statesBaden wübergNew yorkSoult ukpyolsiSouth koreaArtiva alloArndt schotteliusJens pahlMary beth sandinAlexander fudukidisSeog kimDrug administrationUniversity of texas md anderson cancer centerArtiva biotherapeutics incOncology at samsung medical centerInternational conference on malignant lymphoma

Affimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML)

Affimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesBaden wübergSoult ukpyolsiSouth koreaNew yorkArndt schotteliusArtiva alloMary beth sandinSeog kimAlexander fudukidisdirectorJens pahlInternational conference on malignant lymphomaArtiva biotherapeutics incDrug administrationOncology at samsung medical centerUniversity of texas md anderson cancer center

AFM13 Proves Active in Relapsed/Refractory PTCL, Especially AITL

The bispecific antibody AFM13 elicits responses in patients with relapsed/refractory peripheral T-cell lymphoma, a phase 2 study suggests.

Soult ukpyolsiSouth koreaSeog kimSungkyunkwan university school of medicineWon seog kimSungkyunkwan university school

Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH

49% objective response rate (ORR) in heavily pre-treated patients who were naïve to prior CAR-T, with 31% achieving a complete response (CR)Even i.

South koreaSoult ukpyolsiUnited statesSeog kimTammy allenMark hudsonPrnewswire regeneron pharmaceuticals incRegeneron pharmaceuticals incRegeneron genetics centerDrug administrationOncology at sungkyunkwan universityExchange commissionAmerican society of hematologySamsung medical centerEuropean unionEuropean medicines agency

vimarsana © 2020. All Rights Reserved.